Publication Month: Aug 2022 |
Report Code: TIPHE100000855
| No. of Pages:
| Category: Medical Device
| Status: Published
No. of Pages 226
Digital pathology comprises the gaining, organizing, sharing, and interpretation of pathology information. The process involves converting glass slides into digital pathology slides using scanning tools. The generated digital slide image is used for high-resolution viewing, interpretation, and image analysis.
The digital pathology market is segmented on the basis of product, type, application, end user, and geography. By geography, the market is broadly segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. This report offers insights and in-depth analysis of the market with an emphasis on parameters such as market trends and market dynamics, and the competitive analysis of the globally leading market players.
|Market Size Value in||US$ 952.62 Million in 2022|
|Market Size Value by||US$ 1,892.40 Million by 2028|
|Growth rate||CAGR of 12.1% from 2022 to 2028|
|No. of Pages||226|
|No. of Tables||197|
|No. of Charts & Figures||83|
|Historical data available||Yes|
|Segments covered||Product, Type, Application, and End User|
|Regional scope||North America; Europe; Asia Pacific; Latin America; MEA|
|Country scope||US, UK, Canada, Germany, France, Italy, Australia, Russia, China, Japan, South Korea, Saudi Arabia, Brazil, Argentina|
|Report coverage||Revenue forecast, company ranking, competitive landscape, growth factors, and trends|
|Free Sample Copy Available|
Computerization, robotic light microscopy, multiple fiber-optic communications, and digital imaging are among the technologies contributing to the modernization of digital pathology. Healthcare information technology (IT) helps physicians in maintaining optimal workflow, along with allowing them to meet the continuously changing patient expectations. The Aperio ePathAccess software offered by Leica Biosystems enables users to share digital pathology images and case data with experts outside the IT network. Further, frequent advancements in whole-slide imaging (WSI) technology, software applications, LIS/LIMS interface, and high-speed networking are allowing pathologists to fully integrate digital pathology into their workflows. Further, the growing use of microarrays and predictive models, such as API algorithms and hybrid models, is bolstering the demand for digital image analysis. A computer-aided diagnosis integrates image processing with the concepts of physics and mathematics, and computational algorithms for disease diagnosis, anatomical evaluation, and disease progression quantification and risk assessment. Thus, the increasing popularity of computer-aided systems is supporting the digital pathology market growth.
Based on product, the digital pathology market is segmented into scanner, software, storage, and communication system. The scanner segment is further bifurcated into integrated and standalone. The scanner segment held the largest market share in 2022. However, the software segment is expected to register the highest CAGR during the forecast period. Digital pathology software solutions are used for image analysis and data restoring. Companies such as Visiopharm and Indica Labs provide software and solutions for digital pathology.
Based on type, the digital pathology market is bifurcated into human pathology and veterinary pathology. The human pathology segment is likely to hold a larger market share in 2022. Furthermore, the same segment is expected to record a faster CAGR during 2022–2028. The market for the human pathology segment is driven by the increasing number of cancer research projects and a rising number of collaborations among research institutes, universities, and pathology laboratories.
Based on application, the digital pathology market is segmented into disease diagnosis, drug discovery, teleconsultation, and training & education. The drug discovery segment is likely to hold the largest market share in 2022. Furthermore, the same segment is expected to record the highest CAGR during 2022–2028. The central benefit of digital pathology in pharmaceutical research is the ability to apply image analysis algorithms to reduce time and efforts required for subject interpretations. This is critically important to automate dull tasks such as counting cells of interest or estimating protein expression in immunohistochemical assays.
Based on end user, the digital pathology market is segmented into pharma & biotech companies, hospitals, and academics. In 2022, the pharma & biotech companies segment is likely to hold the largest share of the market. Furthermore, the same segment is expected to register the highest CAGR from 2022 to 2028. The increasing use of digital pathology in drug discovery studies and drug toxicology testing is the major factor driving the market for the pharma & biotech companies segment. Biotechnology companies also use digital pathology in biobanking, biopharmaceutical studies, molecular assays, and individualized medicine development.
Organic developments such as product launches and approvals are highly adopted strategies by companies in the digital pathology market. A few of the recent key market developments are listed below: